会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明公开
    • Steel for use as material of cold-rolled steel sheet
    • Stahlfürkaltgewalzte Feinbleche。
    • EP0119088A1
    • 1984-09-19
    • EP84301646.0
    • 1984-03-12
    • NIPPON STEEL CORPORATION
    • Koyama, Kazuo c/o KimitsuseitetsushoHamamoto, Yasuo c/o KimitsuseitetsushoKatoh, Hiroshi c/o KimitsuseitetsushoToyota, Hiromi c/o Kimitsuseitetsusho
    • C22C38/12C22C38/00C21D8/04
    • C21D8/04C22C38/00C22C38/12
    • A steel annealable at low temperature and suitable for use as the material of cold-rolled steel sheet having an excellent formability consists essentially, by weight, of not greater than 0.005% of C, not greater than 0.5% of Mn, not greaterthan 0.1% of P, not greater than 0.005% of N, 0.016 to 0.035% of 0, with the balance being Fe and inevitable impurities, the 0 and at least a part of the Mn existing in the form of fine oxides dispersed substantially uniformly which oxide brings about a structure which imparts the good formability to the steel. A steel sheet may be produced by a method comprising the steps of forming a steel slab from the above-mentioned components by continuous casting, subjecting the steel slab to hot rolling to form a steel sheet, subjecting the hot-rolled steel sheet to cold rolling after pickling, and subjecting the cold-rolled steel sheet to continuous annealing at a low temperature of from 600 to 770°C or to box annealing at a low temperature of from 550 to 680°C.
    • 在低温下可退火并适合用作具有优异成形性的冷轧钢板的材料的钢基本上由不大于0.005%的C,不大于0.5%的Mn,不大于0.1 P的百分比,不大于0.005的N,0.016至0.035%的O,余量为Fe和不可避免的杂质,O和至少部分以细氧化物形式存在的Mn基本均匀地分散,这种氧化物 带来了赋予钢的良好成形性的结构。 可以通过以下方法制造钢板:通过连续铸造从上述组分形成钢坯的方法,对钢坯进行热轧以形成钢板,对热轧钢板进行冷轧 酸洗后,在600〜770℃的低温下对冷轧钢板进行连续退火,或者在550〜680℃的低温下进行框退火。
    • 10. 发明公开
    • Erythromycin derivatives
    • 红霉素衍。
    • EP0321185A2
    • 1989-06-21
    • EP88311785.5
    • 1988-12-13
    • BEECHAM GROUP PLC
    • Davies, John Sidney
    • C07H17/08A61K31/70
    • C07H17/08
    • 9- N ,11- O -methylene derivatives of erythromycin-9-imine (wherein the methylene group is optionally substituted) of the general formula IA or IB:
      or a pharmaceutically acceptable ester or acid addition salt thereof,
      wherein
      R¹ denotes hydrogen, an unsubstituted or substituted hydrocarbon group, a heterocyclyl group, or an acyl group;
      R³ denotes hydrogen or hydroxy;
      R⁶ denotes hydrogen or methyl;
      one of R⁷ and R⁸ denotes hydrogen, hydroxy, alkoxy,alkanoyloxy, amino, substituted amino, or a group of the formula R⁹-SO₂-O-, and the other of R⁷ and R⁸ denotes hydrogen, or
      R⁷ and R⁸ together denote an oxo group, an oxime group, or a substituted oxime group; and
      R⁹ denotes an organic group,
      possess improved acid stability, compared with erythromycin A, whilst retaining good antibacterial activity.
    • 通式IA或IB的红霉素-9-亚胺(其中亚甲基任选被取代)的9-N,11-O-亚甲基衍生物或其药学上可接受的酯或酸加成盐,其中R 1, 1>表示氢,未取代或取代的烃基,杂环基或酰基; R 3表示氢或羟基; R 6表示氢或甲基; R 7和R 8中的一个表示氢,羟基,烷氧基,烷酰氧基,氨基,取代的氨基或式R 9 -SO 2 -O-的基团,R 7和 R 8表示氢,或R 7和R 8一起表示氧代基,肟基或取代的肟基; R 9表示有机基团,与红霉素A相比具有改善的酸稳定性,同时保持良好的抗菌活性。